Insulet Corporation designs and commercializes tubeless, wearable automated insulin delivery technology. Its Omnipod platform, developed from a napkin-sketch concept in 2000, serves over 600,000 customers across 25 countries. Omnipod 5 is described as the world's first tubeless automated insulin delivery system controlled by a smartphone, and is the number one prescribed automated insulin delivery system in the United States.
The company's technical work spans medical devices, wearable and automated insulin delivery, smartphone-controlled device software and diabetes management technology. Engineering efforts sit at the intersection of regulated hardware and consumer-facing software, where device control, algorithm-driven dosing and mobile applications must operate within medical device standards. Industry verticals include healthcare, insulin delivery and digital health.
Insulet is publicly traded on NASDAQ under the ticker PODD and reported annual revenue of $2.1 billion. It operates across North America, Europe, the Middle East and Asia Pacific.
The company was founded by a father seeking to free his son from daily insulin injections, and describes its mission as making diabetes a smaller part of life. It cites a focus on simplicity, freedom and healthier outcomes, advocates for its customer community of "Podders", and states a commitment to sustainable and responsible growth.
